Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04858412 · ClinicalTrials.gov registry record · NA
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
A NA study of COVID-19 Pneumonia and Alcoholic Liver Disease, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04858412: Recruiting NA study of COVID-19 Pneumonia and Alcoholic Liver Disease, sponsored by The Cleveland Clinic.
NCT04858412 is a NA study of COVID-19 Pneumonia and Alcoholic Liver Disease that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 48 participants, below the 254-participant average among 5 other COVID-19 Pneumonia trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04858412, a NA study of COVID-19 Pneumonia and Alcoholic Liver Disease, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with anabolic properties, increases muscle mass and contractile function and enhances immune function. We aim to study the natural course of COVID-19 in patients with ALD and test whether HMB can affect ventilatory deterioration and improve short and long-term morbidity, mortality, and recovery from critical illness in symptomatic COVID-19 patients with ALD.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT β-hydroxy β-methyl butyrate (HMB) enriched amino acid
- DIETARY_SUPPLEMENT Balanced amino acid
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT04858412 shows while recruiting
NCT04858412 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 254-participant average among 5 other COVID-19 Pneumonia trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with COVID-19 Pneumonia appearing as the primary indexed condition, and to 2 interventions - of which β-hydroxy β-methyl butyrate (HMB) enriched amino acid is the first listed.
NCT04858412 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04858412 about?
NCT04858412 is a clinical study titled "Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19". Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with anabolic properties, increases m...
What is the current status of trial NCT04858412?
This trial is currently recruiting. It is a NA study. The enrollment target is 48 participants. The study started on 2021-04-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04858412 study?
This clinical trial studies the following conditions: COVID-19 Pneumonia, Alcoholic Liver Disease.
What interventions are being tested in trial NCT04858412?
The interventions under investigation include: β-hydroxy β-methyl butyrate (HMB) enriched amino acid (DIETARY_SUPPLEMENT), Balanced amino acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04858412?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04858412 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19 Pneumonia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
-
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
A Retrospective Study of COVID-19 Treatments
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI